Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy.

  title={Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy.},
  author={Emanuela Zappia and Simona Casazza and Enrico Pedemonte and Federica Benvenuto and Ivan Bonanni and Ezio Gerdoni and Debora Giunti and Antonella Ceravolo and Francesco Cazzanti and Francesco Frassoni and Gian Luigi Mancardi and Antonio Uccelli},
  volume={106 5},
We studied the immunoregulatory features of murine mesenchymal stem cells (MSCs) in vitro and in vivo. MSCs inhibited T-cell receptor (TCR)-dependent and -independent proliferation but did not induce apoptosis on T cells. Such inhibition was paired with a decreased interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha production and was partially reversed by interleukin-2 (IL-2). Thus, we used MSCs to treat myelin oligodendrocyte glycoprotein (MOG)35-55-induced experimental autoimmune… 

Figures and Tables from this paper

Mesenchymal Stromal/Stem Cells Do Not Ameliorate Experimental Autoimmune Encephalomyelitis and Are Not Detectable in the Central Nervous System of Transplanted Mice.

The data does not provide substantiation for a relevant migration of infused MSCs into the CNS of EAE mice supporting the hypothesis that potential therapeutic efficacy could be based on systemic effects, and Evaluation of possible mechanisms underlying the observed discrepancies in MSC treatment outcomes between different EAE models demands further studies.

Therapeutic Efficacy of Mesenchymal Stem Cells and Mesenchymal Stem Cells-derived Neural Progenitors in Experimental Autoimmune Encephalomyelitis

In comparison to MSCs, allogenic M SCs-NPs are more potent in the attenuation of EAE, and combined therapy with MSC’s and MSCed neural progenitor cells did not provide any benefit over monotherapy with MCCs- NPs.

Bone Marrow‐Derived Mesenchymal Stem Cells Ameliorate Autoimmune Enteropathy Independently of Regulatory T Cells

Evidence is shown that transplantation of MSCs caused global immunosuppression, as measured by increased CD4+ CD8+ thymocyte production and serum interleukin‐10 and decreased serum interferon‐γ, which implicate the intestine as a new site for MSC tolerance induction and should motivate additional studies evaluating the use of M SCs as a treatment for autoimmune enteropathies.

Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis.

The results indicate that stem cells derived from bone marrow may provide a feasible and practical way for neuroprotection, immunomodulation, and possibly remyelination and neuroregeneration in diseases such as multiple sclerosis.

Intravenous Administration of Bone Marrow-Derived Mesenchymal Stem Cells Induces a Switch from Classical to Atypical Symptoms in Experimental Autoimmune Encephalomyelitis

The results suggest that the inflammatory status is important to be considered for administering MSCs in autoimmune pathologies, leading to a further research to clarify the effect of M SCs for multiple sclerosis.

Positive effect of Mesenchymal Stem Cells therapeutic administration on chronic Experimental Autoimmune Encephalomyelitis

It is demonstrated that MSCs ameliorate the clinical course of EAE and hamper the disease relapsing by reducing the areas of demyelinated lesions.

Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis.

Allogeneic MSCs can suppress the manifestations of EAE, yet retain the potential for alloimmunization.

Transplantation of human adipose-derived stem cells overexpressing LIF/IFN-β promotes recovery in experimental autoimmune encephalomyelitis (EAE)

The findings revealed that the pattern of inflammatory and anti- inflammatory cytokines gene expression in the IFN-β/LIF-hADSCs group was reversed compared to the control group and might enhance the treatment efficacy and provide a promising candidate for stem cell-based gene therapy of MS therapy in the future.

Allogeneic Adipose-Derived Mesenchymal Stromal Cells Ameliorate Experimental Autoimmune Encephalomyelitis by Regulating Self-Reactive T Cell Responses and Dendritic Cell Function

It is suggested that mASCs reduce EAE severity, in part, through the impairment of DC and T cell function.



Human mesenchymal stem cells modulate allogeneic immune cell responses.

Insight is offered into the interactions between allogeneic MSCs and immune cells and mechanisms likely involved with the in vivo MSC-mediated induction of tolerance that could be therapeutic for reduction of GVHD, rejection, and modulation of inflammation.

Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness.

The data support an immunoregulatory mechanism wherein hMSCs inhibit T cells indirectly by contact-dependent induction of regulatory APCs with T-cell-suppressive properties and may reveal a physiologic phenomenon whereby the development of a distinct APC population is regulated by the tissue's cellular microenvironment.

Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells.

MSC-mediated inhibition induces an unresponsive T-cell profile that is fully consistent with that observed in division arrest anergy.

Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells.

It is suggested for the first time that human MSCs could suppress monocyte differentiation into DCs, the most potent antigen-presenting cells (APCs), thus indicating the versatile regulation of M SCs on the ultimate specific immune response.

Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects

It is demonstrated that murine MSCs home to lung in response to injury, adopt an epithelium-like phenotype, and reduce inflammation and collagen deposition in lung tissue of mice challenged with BLM.

Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation

Human MSC fail to stimulate allogeneic PBMC or T-cell proliferation in mixed cell cultures, and actively inhibit T- cell proliferation, suggesting that allogeneIC MSC transplantation might be accomplished without the need for significant host immunosuppression.

Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide.

It is suggested that MSCs physically hinder T cells from the contact with APCs in a noncognate fashion and inhibit naive and memory T-cell responses to their cognate antigens.

Human marrow stromal cell therapy for stroke in rat: Neurotrophins and functional recovery

Neurologic benefit resulting from hMSC treatment of stroke in rats may derive from the increase of growth factors in the ischemic tissue, the reduction of apoptosis in the penumbral zone of the lesion, and the proliferation of endogenous cells in the subventricular zone.